Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04647838
Other study ID # KM08
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date January 16, 2020
Est. completion date August 31, 2024

Study information

Verified date November 2020
Source Chungbuk National University Hospital
Contact Ki Hyeong Lee, M.D.
Phone +82432696015
Email kihlee@chungbuk.ac.kr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is to understand efficacy of tepotinib in patients with solid cancers harbouring c-MET amplification or exon 14 mutation who progressed after standard treatment for metastatic disease.


Description:

This study is a basket trial with two strata(NSCLC and other cancer). If MET exon 14 skipping mutation or MET amplification(copy number gain ≥6.0 ) is detected by NGS method, then confirmation of genetic findings by Molecular Steering Committee will be followed. Patient can participate in this trial after confirmation of genetic analysis and reviewing other inclusion/exclusion criteria.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date August 31, 2024
Est. primary completion date February 28, 2023
Accepts healthy volunteers No
Gender All
Age group 19 Years and older
Eligibility Inclusion Criteria: 1. Histologically or cytologically confirmed solid cancers (NSCLC, gastric cancer, colorectal cancer, breast cancer, hepatocellular cancer, head and neck cancer, RCC and other solid cancers) 2. Subjects who are not eligible for surgical and/or local-regional therapies or who have progressive disease (PD) after surgical and/or local-regional therapies 3. Subjects who have disease progression or are intolerant to the prior standard treatment for advanced solid cancers 4. A tumor biopsy (excluding fine needle aspiration and cytology samples) is required for determining MET status (a fresh pretreatment tumor biopsy is recommended but archived tumor sample is acceptable). 5. Patients with MET exon 14 skipping mutation detected by NGS method and c-MET copy number gain (=6.0) in the archival or fresh tumor tissue specimen identified in K-MASTER panel. All genetic findings must be reviewed by the study Molecular Steering Committee, prior to study entry. 6. Male or female, 19 years of age or older 7. Measurable disease in accordance with Response Evaluation Criteria in Solid Tumors (RECIST v 1.1). The target lesion that has received previous local therapy should not be considered as measurable unless clear progression has been documented since the therapy. 8. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 9. Signed and dated informed consent indicating that the subject has been informed of all the pertinent aspects of the trial prior to enrollment 10. Life expectancy judged by the Investigator of at least 3 months Exclusion Criteria: 1. Eligibility criteria: 1. Histologically or cytologically confirmed solid cancers (NSCLC, gastric cancer, colorectal cancer, breast cancer, hepatocellular cancer, head and neck cancer, RCC and other solid cancers) 2. Subjects who are not eligible for surgical and/or local-regional therapies or who have progressive disease (PD) after surgical and/or local-regional therapies 3. Subjects who have disease progression or are intolerant to the prior standard treatment for advanced solid cancers 4. A tumor biopsy (excluding fine needle aspiration and cytology samples) is required for determining MET status (a fresh pretreatment tumor biopsy is recommended but archived tumor sample is acceptable). 5. Patients with MET exon 14 skipping mutation detected by NGS method and c-MET copy number gain (=6.0) in the archival or fresh tumor tissue specimen identified in K-MASTER panel. All genetic findings must be reviewed by the study Molecular Steering Committee, prior to study entry. 6. Male or female, 19 years of age or older 7. Measurable disease in accordance with Response Evaluation Criteria in Solid Tumors (RECIST v 1.1). The target lesion that has received previous local therapy should not be considered as measurable unless clear progression has been documented since the therapy. 8. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 9. Signed and dated informed consent indicating that the subject has been informed of all the pertinent aspects of the trial prior to enrollment 10. Life expectancy judged by the Investigator of at least 3 months 2. Exclusion criteria 1. Prior treatment with any agent targeting the HGF/c-MET pathway 2. Prior EGFR therapy for EGFR activating mutant NSCLC 3. Patients who received local treatment within 4 weeks prior to the first administration of tepotinib (e.g., major surgery, radiation therapy, hepatic arterial embolization, transcatheter arterial chemoembolization, chemoembolization, radiofrequency ablation, percutaneous ethanol injection, or cryoablation). NOTE: palliative radiotherapy should be completed at least 7 days prior to the first administration of the tepotinib. 4. Prior history of organ transplant 5. Laboratory index at screening(refer to protocol) 6. Past or current history of neoplasm other than current cancer, except for curatively treated non-melanoma skin cancer, in situ carcinoma of the cervix, node-negative thyroid cancer or other cancer curatively treated and with no evidence of disease for at least 3 years 7. Known central nervous system (CNS) or brain metastasis that is either symptomatic or untreated 8. Medical history of difficulty swallowing, malabsorption, or other chronic gastrointestinal disease, or conditions that may hamper compliance and/or absorption of the tested products 9. Clinically significant gastrointestinal bleeding within 4 weeks prior to the first administration of tepotinib. 10. Impaired cardiac function(refer to protocol) 11. Hypertension uncontrolled by standard therapies (not stabilized to = 150/90 mmHg) 12. Subject with a family history of long QT syndrome or who take any agent that is known to prolong QT/QTc interval or with a marked prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval > 450 msec) 13. Known human immunodeficiency virus (HIV) infection 14. Subjects who were diagnosed with acute pancreatitis and/or chronic pancreatitis by related symptoms or imaging study. 15. Known or suspected drug hypersensitivity to any ingredients of tepotinib 16. Female subjects who are pregnant or lactating, or males and females of reproductive potential not willing or not able to employ a highly effective method of birth control/contraception to prevent pregnancy from 2 weeks before receiving study drug until 3 months after receiving the last dose of study drug. A highly effective method of contraception is defined as having a low failure rate (< 1% per year) when used consistently and correctly. 17. Concurrent treatment with anti-cancer therapy 18. Substance abuse, other acute or chronic medical or psychiatric condition that may increase the risk associated with trial participation in the opinion of the Investigator 19. Participation in another interventional clinical trial within 28 days prior to the first administration of tepotinib or within a time period that is less than the cycle length for the investigational treatment (whichever is shorter), or if the subject has any AE caused by the investigational treatment that has not recovered to Grade 0-1 20. Previous anticancer treatment-related toxicities not recovered to baseline or Grade 1 (except alopecia) prior to administratin of tepotinib 21. Subjects with any concurrent medical condition or disease that will potentially compromise the conduct of the study at the discretion of the Investigators 22. Clinically significant third space fluid accumulation (despite the use of diuretics), e.g., uncontrolled pleural effusion or ascites 23. Uncontrolled venous or arterial thromboembolism

Study Design


Intervention

Drug:
Tepotinib
Tepotinib 500mg (2 tablets of 250mg) per day D1-21 orally, once daily

Locations

Country Name City State
Korea, Republic of Dankook University Hospital Cheonan
Korea, Republic of Chungbuk National University Hospital Cheongju-si Chungcheongbuk-do
Korea, Republic of Keimyung University Dongsan Hospital Daegu
Korea, Republic of Konyang University Hospital Daejeon
Korea, Republic of National Cancer Center Goyang-si
Korea, Republic of Hallym University Dongtan Sacred Heart Hospital Hwaseong-si
Korea, Republic of Chonnam National University Hwasun Hospital Hwasun Chonnam
Korea, Republic of Gachon University Gil Medical Center Incheon
Korea, Republic of The Catholic University of Korea Incheon St. Marry Hospital Incheon
Korea, Republic of Gyeongsang National University Hospital Jinju
Korea, Republic of Inje University Haeundae Pain Hospital Pusan
Korea, Republic of Kosin University Gaspel Hospital Pusan
Korea, Republic of Seoul National University Bundang Hospital Seongnam-si
Korea, Republic of Chungang University Hospital Seoul
Korea, Republic of Gangnam Severance Hospital Seoul
Korea, Republic of Inje University Sanggye Paik Hospital Seoul
Korea, Republic of Korea University Anam Hospital Seoul
Korea, Republic of Korea University Guro Hospital Seoul
Korea, Republic of Samsung Medical Center Seoul
Korea, Republic of Seoul National University Hospital Seoul
Korea, Republic of Severance Hospital Seoul
Korea, Republic of Pusan National University Yangsan Hospital Yangsan

Sponsors (2)

Lead Sponsor Collaborator
Chungbuk National University Hospital Merck KGaA, Darmstadt, Germany

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Objective response rates (RECIST1.1) Objective response will be determined according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as assessed by investigator.
Objective response is defined as either a confirmed complete response (CR) or partial response (PR) from first administration of trial treatment to first observation of progressive disease (PD). CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. PD is defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.
Baseline up to 20 months
Secondary Progression free survival Progression free survival as assessed by investigators is defined as the time (in months) from the first administration of trial treatment to the date of the first documentation of PD (based on independent review) or death due to any cause within 84 days of the last tumor assessment, whichever occurs first Baseline until PD or death within 84 days of last tumor assessment; assessed up to 20 months
Secondary Disease control rate Objective disease control is defined as either a confirmed CR or PR, or stable disease (SD) lasting at least 12 weeks (84 days) as assessed by investigator. CR: Disappearance of all evidence of target and non-target lesions. Baseline up to 20 months
Secondary Overall survival Overall survival is defined as the time (in months) from first trial treatment administration to the date of death. Baseline until death, assessed up to 20 months
Secondary Toxicity and drug compliance This outcome measure will be presented as the percentage of subjects with any adverse event (AE). Percentages are calculated using total number of subjects per treatment cohort as the denominator. From the first dose of study drug administration until 33 days after the last dose of study drug administration, assessed up to 20 Months
See also
  Status Clinical Trial Phase
Recruiting NCT05691608 - MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2 N/A
Recruiting NCT05580991 - Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors Phase 1
Active, not recruiting NCT02846038 - Understanding Communication in Healthcare to Achieve Trust (U-CHAT)
Recruiting NCT05159388 - A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors Phase 1/Phase 2
Completed NCT03181854 - Randomized Controlled Trial of Integrated Early Palliative Care N/A
Recruiting NCT06014502 - Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors Phase 1
Recruiting NCT05981703 - A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors Phase 1
Recruiting NCT04107311 - Prospective Analysis of Intestinal Microbiome and Autoimmune Panels as Predictors of Toxicity in ImmunOncology Patients
Active, not recruiting NCT04078152 - Durvalumab Long-Term Safety and Efficacy Study Phase 4
Completed NCT02250157 - A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies Phase 1
Recruiting NCT05566574 - A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer Phase 1/Phase 2
Recruiting NCT03943004 - Trial of DFP-14927 in Advanced Solid Tumors Phase 1
Recruiting NCT06036836 - Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) Phase 2
Recruiting NCT05798546 - Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02) Phase 1
Recruiting NCT05525858 - KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
Terminated NCT04586335 - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT00479128 - Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors Phase 1
Recruiting NCT04143789 - Evaluation of AP-002 in Patients With Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT04550663 - NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors Phase 1
Completed NCT03980041 - Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) Phase 2